24.09.2012 - Syngenta is set to buy two biotech companies: The Swiss firm is willing to pay up about €500m for seed maker Devgen NV and Pasteuria Biosciences.
Syngenta announced an offer to acquire all outstanding shares of Devgen NV at a price of €16 in cash per share, valuing the Belgian hybrid rice seed producer at €403m in total. The offer price represents a premium of 70% to Devgen's closing price on NYSE Euronext Brussels on 20 September 2012, the day before the tender offer was made public.
The Belgian group posted sales of €25.5m and an operational loss of €6.3m in 2011. Created in 1997, the company employs 250 people and among its products is a hybrid rice developed for India and South-east Asia. The asset will have a “very significant impact” on Syngenta’s $500 million rice business, Chief Operating Officer Davor Pisk said in an interview today. "We are also buying their competence in RNAi technology which are relevant for us across a broad range of crops“, added Syngenta spokeswoman Jennifer Gough.
This is Syngenta's second deal announced within a week. Only days before, Swiss company revealed its plans to acquire Pasteuria Biosciences for €87m. Since 2011, Syngenta and the US company have had an exclusive global technology partnership to develop and commercialise biological products to control plant-parasitic nematodes, using the naturally occurring soil bacteria Pasteuria spp.
With its acquisition strategy, Syngenta reacts to the increasingly fierce competition with agribusiness companies Bayer and BASF both of Germany. BASF recently announced the intention to buy Becker Underwood for €785m, while Bayer decided months ago to purchase US-based AgraQuest for €340m plus milestone payments.
26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.
24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.
20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.
18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.
11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.
09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.
04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.
03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.